欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2022, Vol. 27 ›› Issue (4): 423-427.doi: 10.12092/j.issn.1009-2501.2022.04.011

• 心血管疾病药物治疗最新研究进展 • 上一篇    下一篇

β受体阻滞剂与高血压治疗

崔素梅1,崔兆强2   

  1. 1山东大学齐鲁医院,济南 250012;2复旦大学附属中山医院,上海 200032
  • 出版日期:2022-04-26 发布日期:2022-05-17
  • 通讯作者: 崔兆强,男,博士,教授,博士生导师,研究方向:高血压病发病机制与临床治疗。 E-mail: zhaoq_cui@163.com
  • 作者简介:崔素梅,女,博士,医师,助理研究员,研究方向:急危重症心血管病。 E-mail: 530905281@qq.com
  • 基金资助:
    国家自然科学基金(82002017)

Application of β-blockers for hypertension

CUI Sumei1, CUI Zhaoqiang2   

  1. 1 Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan 250012, China; 2 Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China
  • Online:2022-04-26 Published:2022-05-17

摘要:

β受体阻滞剂是治疗高血压等多种心血管疾病的基础药物之一。但是,近年来有研究质疑甚至否定β受体阻滞剂的降压效益,对部分心血管医生造成了困惑。基于对多项研究的系统分析,笔者认为β受体阻滞剂一线降压地位仍不可动摇,并在本文进行了详细论证。

关键词: β受体阻滞剂, 高血压, 抗高血压药物

Abstract:

β-blockers are widely administered to patients with various cardiovascular diseases including hypertension. However, in recent years, studies have questioned or even denied the antihypertensive effect of β-blockers, which has caused confusion to cardiovascular clinicians. Based on the systematic analysis of a number of studies, the author believes that β-blockers still remain the status as the first-line antihypertensives.

Key words: β-blocker, hypertension, antihypertensives

中图分类号: